Regenerx Biopharmaceuticals Inc., of Rockville, Md., said it received orphan drug designation from the FDA for its Thymosin beta 4 (Tbeta4) candidate for treating neurotrophic keratopathy (NK), a serious degenerative disease of the corneal epithelium.